Frontiers in Pharmacology · 2 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review synthesizes preclinical and observational evidence on how endocrine-disrupting chemicals impair glucose-6-phosphate dehydrogenase enzyme activity at transcriptional, translational, and posttranslational levels. The authors suggest that EDC-mediated G6PD impairment may contribute to dysregulated oxidative stress, lipid, and glucose metabolism.
EDCs activate peroxisome proliferator-activated receptors and disrupt hormone metabolism, leading to lipid, glucose, and energy metabolism dysregulation. The authors note that individuals with G6PD deficiency may be more vulnerable to EDC-induced metabolic and endocrine effects.
